

# Active substances set

**Search phrase:** cabozantinib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Liver cancer

| | | |
|---|---|---|
| **Cabozantinib** | Cabozantinib is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. | NO REIMBURSEMENT<br>ESMO |

## Kidney cancer

| | | |
|---|---|---|
| **Cabozantinib** | Cabozantinibis indicated as monotherapy for advanced renal cell carcinoma (RCC): - as first-line treatment of adult patients with intermediate or poor risk, - in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabozantinib, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |